Transaction DateRecipientSharesTypePriceValue
1st December 2020Michael A Metzger15,000Open or private sale$22.97$344,512.50
1st December 2020Michael A Metzger15,000Exercise of derivative$7.20$108,000.00
23rd November 2020Peter Ordentlich5,684Open or private sale$23.33$132,602.60
23rd November 2020Peter Ordentlich7,954Open or private sale$23.58$187,594.29
23rd November 2020Peter Ordentlich5,684Exercise of derivative$3.08$17,506.72
23rd November 2020Peter Ordentlich16,334Open or private sale$22.89$373,924.46
23rd November 2020Peter Ordentlich24,288Exercise of derivative$3.08$74,807.04
10th November 2020Briggs Morrison17,466Open or private sale$20.06$350,312.07
10th November 2020Briggs Morrison17,466Exercise of derivative$7.20$125,755.20
9th November 2020Briggs Morrison62,938Open or private sale$20.04$1,261,264.93
Syndax Pharmaceuticals
Syndax Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005.

Ticker: SNDX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1395937
Employees: 35
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $54 M (117%)
Assets, Current: $192 M (207%)
Property, Plant and Equipment, Net: $237 Th (-15%)
Other Assets, Noncurrent: $82 Th (-58%)
Assets: $193 M (203%)
Accounts Payable, Current: $2 M (-70%)
Liabilities, Current: $12 M (-32%)
Other Liabilities, Noncurrent: $3 Th (-40%)
Liabilities: $45 M (40%)
Common Stock, Value, Issued: $4 Th (33%)
Common Stock, Shares, Issued: $39 M (41%)
Additional Paid in Capital, Common Stock: $675 M (28%)
Retained Earnings (Accumulated Deficit): $528 M (6%)
Stockholders' Equity (Parent): $148 M (0%)
Liabilities and Equity: $193 M (203%)
Revenue: $379 Th (0%)
Research and Development: $11 M (-46%)
General and Administrative Expenses: $6 M (-49%)
Operating Income/Loss: $17 M (-47%)
Other Income, net: $452 Th (-23%)